Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeldesivir for Nonhospitalized COVID-19 (OAKTREE)
NCT05715528Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2023
- Primary completion
- Nov 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of obeldesivir in coronavirus disease 2019 (COVID-19), sponsored by Gilead Sciences. Started Feb 2023; status: completed.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05715528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715528.